SmithKline Label Comprehension Studies Explore Denavir Misuse Potential
This article was originally published in The Tan Sheet
Executive Summary
The possibility that SmithKline Beecham's Denavir might be used in an OTC setting by immunocompromised consumers as well as for the treatment of genital herpes was explored in four label comprehension studies presented by the company at a joint meeting of FDA's Nonprescription and Antiviral Drugs Advisory Committees in Bethesda, Md. Dec. 1.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning